Post Archive
-

Etcembly reveals world’s first immunotherapy drug designed using generative AI technology
-

Catching Agilent’s eye – Cobalt’s turbocharged growth story
-

Human touch a USP in the global AI race – Oxford Dynamics’ story
-

Finding North – from spin out to acquisition – Oxsensis’ story
-

Tackling the global biodiversity crisis through matchmaking and AI – Agtelligence’s story
-

‘A magic bullet for immunotherapy’ – Etcembly’s story
-

The fuel behind scientific discovery – Quantum Detectors’ story
-

New ‘out of this world’ conference centre opens at Harwell
-

Harwell Green Week 2023 highlights
-

UKAEA and Oxford Sigma collaborate to help demonstrate the commercial viability of fusion energy